Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Germ Cell Neoplasms, Hodgkin's Disease, Immunodeficiency Diseases, Multiple Myeloma, Myelodysplastic Syndromes, Non-Hodgkin's Lymphoma
Conditions
Brief summary
To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.
Detailed description
To provide an IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant or cellular therapies for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach. To provide a consent mechanism for the retrospective study of cellular products, when available, if there is a specific question to be addressed.
Interventions
None listed
Sponsors
Wake Forest University Health Sciences
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
Planned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant
Exclusion criteria
Participation in any other treatment research protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Data followup | 1 year | Gather basic survival and complication data for operational and research databases for ongoing regulatory and future operational queries |
Countries
United States
Contacts
CONTACTDianna Howard, MD
PRINCIPAL_INVESTIGATORDianna Howard, MD
Wake Forest University Health Sciences
Outcome results
None listed